EGFR and esophageal squamous cell carcinoma: Considering that EGFR stimulates intracellular Ca2+ release and SOCE-mediated Ca2+ influx regulates EGFR downstream AKT and ERK activity, we hypothesize that combined afatinib and RP4010 may achieve an enhanced anticancer effect in ESCC cells.